Norman Heching

P4.07D.01 Neoadjuvant Osimertinib Followed by Radiation And/or Surgery in Stage III EGFR-Mutant NSCLC: An Open-Label, Single-Arm, Phase 2 Study

N. Peled, W. Kian, B. Krayim, Julia Dudnik et autres

il, us (code pays fourni par la source)

EP12.01-76 Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC

Bilal Krayim, Waleed Kian, I.S. Granot, D. Kahala et autres

us (code pays fourni par la source)

1343P Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC

Bilal Krayim, Waleed Kian, Norman Heching, Ayman Salhab et autres

il (code pays fourni par la source)

Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study

Nir Peled, Laila C. Roisman, Esther Levison, Julia Dudnik et autres

il (code pays fourni par la source)

[FDG PET/CT FOR TREATMENT RESPONSE ASSESSMENT IN CANCER].

Rachel Bar‐Shalom, Ora Rosengarten, Norman Heching, Yehonatan Turner et autres

INTRODUCTION: FDG PET/CT (fluorodeoxyglucose (FDG)-positron emission tomography (PET) computed tomography (CT)) imaging reflects functional-metabolic changes occurring within the malignant process in response to therapy. Since these changes usually precede anatomic alterations, this imaging technique is highly valuable in assessing response during and …

il (code pays fourni par la source)

Intravascular Small Cell Carcinoma Disguised as Pulmonary Embolism.

Ariel Rokach, Sarit Hochberg-Klein, Nissim Arish, Victoria Doviner et autres

il (code pays fourni par la source)

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth et autres

us, ru, de, jp, at, tr, kr, it, ua, es, cz, pl, hu, bg, gb (code pays fourni par la source)

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth et autres

es, ru, us, de, jp, ua, at, tr, kr, it, cz, pl, hu, bg, gb (code pays fourni par la source)

Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

Volker Heinemann, Navesh Sharma, Jens Ricke, Marc Peeters et autres

au, de, us, fr, be, nz (code pays fourni par la source)

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, Navesh Sharma, Julien Taı̈eb, Volker Heinemann et autres

Background Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining …

gb, au, us, fr, de, be, nz (code pays fourni par la source)

Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer

Esther Tahover, Amiel Segal, Rut Isacson, Ora Rosengarten et autres

Dexrazoxane is indicated as a cardioprotective agent for patients receiving doxorubicin who are at increased risk for cardiotoxicity. Concerns have been raised on the use of dexrazoxane, particularly in adjuvant therapy, because of the risk of interference with the antitumor effect of …

il (code pays fourni par la source)

The diagnostic and prognostic value of ProGRP in lung cancer.

Benjamin Nisman, Haim Biran, Nili Ramu, Norman Heching et autres

AIM: To investigate the diagnostic and prognostic significance of pro-gastrin-releasing peptide (ProGRP) in non-small cell (NSCLC) and small cell lung cancer (SCLC) and compare this marker with other known serum markers in lung cancer. PATIENTS AND METHODS: Serum levels of ProGRP, neuron-specific …

il (code pays fourni par la source)